Efficacy Study of Rapamycin- vs. Zotarolimus-Eluting Stents to Reduce Coronary Restenosis

NCT00598533 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

3002

Enrollment

OTHER

Sponsor class

Conditions

Coronary Heart Disease

Interventions

DEVICE: Rapamycin + Probucol-eluting stent (ISAR stent)
DEVICE: polymer based Zotarolimus-eluting stent (Endeavor Resolute)

Sponsor

Deutsches Herzzentrum Muenchen